Coherus Oncology reports 75% response rate for tagmokitug in ESCC
Coherus Oncology has released interim clinical data from its TREGCHECK development programme evaluating tagmokitug, an investigational anti-CCR8 monoclonal antibody, across multiple solid tumour settings. The headline finding is a confirmed overall response rate of 75% in evaluable first-line esophageal squamous cell carcinoma patients, irrespective of PD-L1 status, rising to 89% after the data cutoff date of 14 October 2026 once two additional partial responses were confirmed.
Tagmokitug is designed to selectively deplete CCR8-positive regulatory T cells within the tumour microenvironment, a mechanism the company positions as a strategy to overcome immune resistance. In the first-line ESCC cohort, it was given in combination with toripalimab (Coherus's approved PD-1 inhibitor, marketed as LOQTORZI) alongside 5-fluorouracil and cisplatin chemotherapy. Among PD-L1-positive patients, the confirmed response rate was 100%, compared with a standard-of-care benchmark of 44% to 59% for PD-1-plus-chemotherapy regimens in that subgroup, according to figures cited by the company.
Second-line data and broader programme
In the second-line ESCC cohort, patients randomised to the higher 700 mg tagmokitug dose achieved a median progression-free survival of 5.5 months, against an approximate standard-of-care benchmark of 3.4 months for chemotherapy alone. A clinical benefit rate of 33.3% was observed in that arm, with durable stable disease consistent with an immuno-oncology-driven mechanism. Clear dose-response differences between the 300 mg and 700 mg arms support the company's selection of the higher dose for expansion cohorts.
Across more than 120 patients treated in combination with toripalimab, no new safety signals were identified beyond those associated with PD-1 checkpoint inhibitor therapy. Immune-related adverse events of all grades occurred in 40% of patients, with 20% experiencing Grade 3 to 5 events. The most common treatment-related adverse events were infusion-related reactions (25%), fatigue (19%) and rash (16%). No Grade 5 treatment-related adverse events were reported. Coherus plans to expand enrolment in both ESCC cohorts and is also advancing a combination study with a T-cell engager in metastatic castration-resistant prostate cancer.
Market context and competitive landscape
Esophageal squamous cell carcinoma carries a high global burden, concentrated particularly in East Asia and parts of Africa. Approved first-line options in the United States remain limited, and no PD-1 inhibitor has regulatory clearance in PD-L1-negative ESCC in the US market, a gap that Coherus explicitly highlights as a potential differentiator for tagmokitug. Toripalimab is already established as a first-line standard of care for ESCC in Europe and China, giving Coherus an existing commercial anchor in ex-US markets.
CCR8-targeted Treg depletion is an emerging mechanism with several programmes in early development across the industry, making the ESCC response data strategically significant for Coherus's competitive positioning. Chief executive Denny Lanfear said the emerging ESCC data provide "a clear and efficient path for advancing the development of tagmokitug in esophageal cancer across both indications," while chief medical officer Rosh Dias described the totality of findings as "clinical proof of concept" for the programme.
Key caveats remain. Efficacy cohorts are small, with as few as eight patients contributing to the first-line ORR figure at the data cutoff, and the trial has not yet reported mature overall survival or long-term duration-of-response data. Full results are expected as the programme matures and enrolment expands. Investors will be watching for a randomised confirmatory cohort design and regulatory feedback before drawing firm conclusions about tagmokitug's commercial trajectory in what is a highly competitive immuno-oncology segment.